Tag: Proteomics

Therapeutic targets supported by robust genetic evidence are more than twice as likely to result in successful drug development, highlighting the critical importance of effective target identification. This process is a fundamental, initial step in the discovery of new medications and therapies for disease treatment.

According to the National Institutes of Health, while the human genome contains approximately 4,500 genes considered part of the 'druggable genome', existing clinical drugs target only a few hundred of these. Therefore, understanding **what is target identification in druggable** is a critical first step in discovering new medications and unlocking the full potential of these untapped targets.

An estimated 90% of drugs that enter clinical trials ultimately fail, with a significant portion of these failures attributed to a lack of efficacy [1.6.3]. This staggering statistic underscores a foundational question in pharmacology: how do you identify a drug target that leads to a successful therapy?